Cuc Thi Thu Nguyen1, Binh Thanh Nguyen2, Thuy Thi Thu Nguyen3, Fabio Petrelli4, Stefania Scuri4, Iolanda Grappasonni4. 1. Department of Pharmaceutical Administration and Economics, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hoan Kiem, Hanoi, Vietnam. cucnguyen.pharm@gmail.com. 2. Department of Pharmaceutical Administration and Economics, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hoan Kiem, Hanoi, Vietnam. 3. Department of Organization and Drug Administration, Faculty of Pharmacy, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam. 4. School of Medicinal and Health Products Sciences, University of Camerino, Camerino, Marche, Italy.
Abstract
PURPOSE: This study aims to evaluate the quality of life (QoL) of chronic myeloid leukemia (CML) patients prescribed with nilotinib as a second-line therapy and explores the influential factors. METHODS: A multicenter retrospective survey was conducted via face-to-face interviews based on the EORTC QLQ-C30 questionnaire. A total of 121 adult CML patients resistant to imatinib and used nilotinib for at least 3 months were enrolled. The influential features were assessed by multiple linear regression models. RESULTS: Patients had the mean age of 47.49 (SD = 13.67) years, dominated by middle-aged and male groups. The mean scores of functions ranged from 75 to 83, and those of symptoms were from 5 to 28, with the highest of fatigue (28.28), insomnia (22.87), and pain (21.07). The mean global health status/QoL score was 67.70 (SD = 16.80) with considerable financial difficulties (52.34 (SD = 32.15)). Male patients reported higher functional scores and fewer symptoms compared with female patients. All aspects of QoL became worse with increasing age. Besides age and gender, level of education, duration of nilotinib usage, and comorbidities were also significantly influential factors in many QoL domains. A predicted model for expected mean scores of QoL domains was built based on these factors. CONCLUSIONS: The CML patients treated with nilotinib had the above-moderate QoL scores, a light decrease of functional scores, great financial difficulties, and still experienced symptoms. Strategies and more therapeutic considerations to enhance QoL for CML patients targeted toward women, the old, low educational level, and long duration of nilotinib usage, and many comorbidities are needed in the setting.
PURPOSE: This study aims to evaluate the quality of life (QoL) of chronic myeloid leukemia (CML) patients prescribed with nilotinib as a second-line therapy and explores the influential factors. METHODS: A multicenter retrospective survey was conducted via face-to-face interviews based on the EORTC QLQ-C30 questionnaire. A total of 121 adult CML patients resistant to imatinib and used nilotinib for at least 3 months were enrolled. The influential features were assessed by multiple linear regression models. RESULTS: Patients had the mean age of 47.49 (SD = 13.67) years, dominated by middle-aged and male groups. The mean scores of functions ranged from 75 to 83, and those of symptoms were from 5 to 28, with the highest of fatigue (28.28), insomnia (22.87), and pain (21.07). The mean global health status/QoL score was 67.70 (SD = 16.80) with considerable financial difficulties (52.34 (SD = 32.15)). Male patients reported higher functional scores and fewer symptoms compared with female patients. All aspects of QoL became worse with increasing age. Besides age and gender, level of education, duration of nilotinib usage, and comorbidities were also significantly influential factors in many QoL domains. A predicted model for expected mean scores of QoL domains was built based on these factors. CONCLUSIONS: The CML patients treated with nilotinib had the above-moderate QoL scores, a light decrease of functional scores, great financial difficulties, and still experienced symptoms. Strategies and more therapeutic considerations to enhance QoL for CML patients targeted toward women, the old, low educational level, and long duration of nilotinib usage, and many comorbidities are needed in the setting.
Authors: Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim Journal: J Natl Cancer Inst Date: 2011-03-21 Impact factor: 13.506
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann Journal: Blood Date: 2013-06-26 Impact factor: 22.113